Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lumigan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Objective: Determine the prices and price variation of the prostaglandin analogs (PGAs) used in the United States and examine… Expand
2016
2016
Aim The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF… Expand
Highly Cited
2010
Highly Cited
2010
  • S. Law
  • Clinical ophthalmology
  • 2010
  • Corpus ID: 14691751
Eyelashes hypotrichosis is a condition indicated by an inadequate amount of eyelashes. Hypertrichosis of eyelashes, characterized… Expand
2010
2010
PURPOSE To quantify the aqueous humor (AH) concentrations of bimatoprost (amide), travoprost (isopropyl ester), and their… Expand
2009
2009
Objective Many researches have demonstrated the lowing-intraocular pressure(IOP) effects of bimatoprost and timolol.However,no… Expand
Highly Cited
2004
Highly Cited
2004
PURPOSE To report a new adverse effect related to treatment with bimatoprost. CASE REPORTS Serial clinical examination of three… Expand
2004
2004
espanolObjetivo: Evaluar el coste/ano y el coste/eficacia hipotensora de los farmacos topicos antiglaucomatosos. Metodos: Este… Expand
Highly Cited
2003
Highly Cited
2003
PURPOSE To compare the efficacy and safety of topical bimatoprost (LUMIGAN; Allergan, Inc., Irvine, CA) once daily with that of… Expand
Highly Cited
2003
Highly Cited
2003
The ability of a number of prostaglandin F2α(PGF2α) analogs to mobilize intracellular Ca2+ [Ca2+]i and to compete for [3H]PGF2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 2
  • figure 3
Review
2001
Review
2001
Bimatoprost (Lumigan) is a pharmacologically unique and highly efficacious ocular hypotensive agent. It appears to mimic the… Expand